Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.

MLA

Kinzler, Eric R., et al. “Relative Oral Bioavailability of an Abuse-Deterrent, Extended-Release Formulation of Morphine Versus Extended-Release Morphine: A 2-Period, Single-Dose, Randomized Crossover Study in Healthy Subjects.” Clinical Therapeutics, vol. 40, no. 8, Aug. 2018, pp. 1357–65. EBSCOhost, https://doi.org/10.1016/j.clinthera.2018.06.010.

APA

Kinzler, E. R., Pantaleon, C., & Aigner, S. (2018). Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. Clinical Therapeutics, 40(8), 1357–1365. https://doi.org/10.1016/j.clinthera.2018.06.010

Chicago

Kinzler, Eric R, Carmela Pantaleon, and Stefan Aigner. 2018. “Relative Oral Bioavailability of an Abuse-Deterrent, Extended-Release Formulation of Morphine Versus Extended-Release Morphine: A 2-Period, Single-Dose, Randomized Crossover Study in Healthy Subjects.” Clinical Therapeutics 40 (8): 1357–65. doi:10.1016/j.clinthera.2018.06.010.